Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
September 8, 2016
bluebird bio (BLUE) P3 Study of LentiGlobin™ with Transfusion-Dependent Beta-Thalassemia - BUY
September 7, 2016
Organovo Holdings (ONVO) preclinical product and service portfolio, allows study of the effects of drug exposure on a key portion of the human kidney
September 7, 2016
Fate Therapeutics (FATE) and Memorial Sloan Kettering Cancer Center launch Partnership
September 7, 2016
BioLife Solutions (BLFS), cash getting tight?
September 6, 2016
Northwest Bio (NWBO) regains NASDAQ compliance
September 6, 2016
Sangamo BioSciences (SGMO) Receives Orphan Drug Designation From for SB-FIX
August 31, 2016
Asterias Biotherapeutics (NYSEMKT: AST) Cleared to begin highest dosing in AST-OPC1 Study
August 30, 2016
OncoCyte Corporation (NYSEMKT: OCX) 3.24 M unit sale with 100% warrant coverage raises $10.5 M
August 26, 2016
RegMed Investors (RMi) Financial results/Earnings Scorecard - Q2/2016 - to date
August 25, 2016
Cesca Therapeutics Inc. (KOOL) cleans up the balance sheet with debt conversion
August 23, 2016
Northwest Bio (NWBO) reprices warrants to raise cash
August 23, 2016
Stemline Therapeutics (STML) receives Breakthrough Therapy Designation from U.S. FDA for SL-401
August 17, 2016
Mesoblast (MESO) Rheumatic diseases patent award drives stock pricing
August 16, 2016
StemCells (STEM) merges with Microbot Medical Ltd.
August 9, 2016
Fibrocell Science (FCSC) ditches share and warrant offering for $25 M convertible promissory notes and warrants
August 9, 2016
Immunocellular (NYSEMKT: IMUC) files 47 M shares offering at $0.16 with 32.25 M warrants to raise $7.4 M
August 9, 2016
Pluristem’s (PSTI) $8 M Grant from Europe’s Horizon 2020 Program for P3 CLI study
August 9, 2016
Mesoblast (MESO) cell treatment shows promise in rheumatoid arthritis - BUY
August 8, 2016
Fibrocell Science (FCSC) files for an underwritten public offering.
August 8, 2016
Fate Therapeutics (FATE) 5.2 M shares offering to raise $10.3 M in private placement priced at $1.96
August 4, 2016
Cesca Therapeutics (KOOL) cashes in on upside move pricing $2.5 M Registered Direct Offering
August 3, 2016
Cesca Therapeutics (KOOL) Promising results as shares jump +31.01% - SELL on slipping momentum
July 27, 2016
uniQure (QURE) clinical data in patients with Severe Hemophilia B
July 27, 2016
Caladrius Biosciences (CLBS) will affect a 1-for-10 reverse stock split, be ready for an offering
July 27, 2016
Pluristem (PSTI) PLX-PAD P3 trial - the hype endures
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.